Company Performance - Novavax (NVAX) ended the recent trading session at $6.85, showing a -2.28% change from the previous day's closing price, which lagged behind the S&P 500's daily loss of 0.13% [1] - Over the past month, shares of Novavax gained 6.05%, outperforming the Medical sector's loss of 0.96% and the S&P 500's gain of 3.39% [1] Upcoming Earnings - Analysts predict Novavax will report an EPS of -$0.19, indicating a 119.19% decline compared to the same quarter last year [2] - The consensus estimate for quarterly revenue is $118 million, down 71.6% from the year-ago period [2] Annual Forecast - Zacks Consensus Estimates forecast earnings of $2.48 per share and revenue of $1.05 billion for the year, reflecting changes of +301.63% and +53.6%, respectively, compared to the previous year [3] - Recent revisions to analyst forecasts for Novavax are important as they reflect near-term business trends, with positive revisions indicating a favorable business outlook [3] Valuation Metrics - Novavax has a Forward P/E ratio of 2.83, significantly lower than the industry average Forward P/E of 19.79, suggesting that Novavax is trading at a discount [6] - The company currently has a PEG ratio of 0.09, while the Medical - Biomedical and Genetics industry has an average PEG ratio of 1.75 [7] Industry Context - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 91, placing it in the top 37% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Group 1: Stock Performance - Novavax (NVAX) closed at $6.97, with a daily increase of +1.9%, outperforming the S&P 500's gain of 0.14% [1] - Over the last month, Novavax shares decreased by 1.44%, while the Medical sector lost 1.34% and the S&P 500 gained 3.97% [1] Group 2: Upcoming Earnings - The upcoming EPS for Novavax is projected at -$0.12, indicating a 112.12% decline compared to the same quarter last year [2] - Revenue is estimated at $130.5 million, reflecting a 68.59% decrease from the corresponding quarter of the previous year [2] Group 3: Fiscal Year Estimates - For the entire fiscal year, earnings are projected at $2.65 per share, representing a +315.45% change from the previous year [3] - Revenue for the fiscal year is estimated at $1.07 billion, indicating a +56.76% change from the prior year [3] Group 4: Analyst Estimates and Rankings - Recent modifications to analyst estimates for Novavax indicate changing near-term business trends, with positive revisions suggesting optimism [4] - The Zacks Rank system, which includes estimate changes, currently ranks Novavax at 3 (Hold) [6] Group 5: Valuation Metrics - Novavax has a Forward P/E ratio of 2.58, which is a discount compared to the industry average Forward P/E of 18.51 [7] - The PEG ratio for Novavax is 0.06, significantly lower than the industry average PEG ratio of 1.54 [8] Group 6: Industry Ranking - The Medical - Biomedical and Genetics industry, which includes Novavax, has a Zacks Industry Rank of 74, placing it in the top 30% of over 250 industries [8][9] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [9]

Group 1: Canopy Growth - Canopy Growth has been a disappointing investment over the past five years, with a significant decline in net revenue and increased losses per share [3][4] - The cannabis industry faces challenges such as legal and regulatory issues, competition from illicit markets, and oversupply, particularly in Canada [5][6] - Despite cost-cutting efforts and a focus on in-demand products, the long-term outlook for Canopy Growth remains bleak, with expectations of further stock decline [6][7] Group 2: Novavax - Novavax reported substantial revenue growth in the first quarter, with revenue of $666.7 million and a net income of $518.6 million, a significant improvement from the previous year [8] - The company has positive results from phase 3 studies for its influenza and combination COVID-19 vaccines, along with partnerships with major pharmaceutical companies [8][9] - However, the long-term sustainability of Novavax's performance is questionable due to market unpredictability, competition from leaders like Moderna and Pfizer, and reliance on external funding for future trials [10][12][13]

Core Viewpoint - Novavax has experienced a significant decline in stock performance, with a return of -10.9% over the past month, contrasting with the S&P 500's +5.2% and the Zacks Medical - Biomedical and Genetics industry's +0.9% [2] Earnings Estimates - For the current quarter, Novavax is projected to report a loss of $0.12 per share, reflecting a -112.1% change year-over-year, with the consensus earnings estimate for the fiscal year at $2.65, indicating a +315.5% change [5][6] - The consensus earnings estimate for the next fiscal year is $0.4, which represents a -84.8% change from the previous year [6] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $130.5 million, indicating a year-over-year decline of -68.6%. For the current fiscal year, the estimate is $1.07 billion (+56.8%), while for the next fiscal year, it is $516.45 million (-51.7%) [11] Last Reported Results and Surprise History - In the last reported quarter, Novavax achieved revenues of $666.66 million, a +610.3% year-over-year increase, with an EPS of $2.93 compared to -$1.05 a year ago. The revenue exceeded the Zacks Consensus Estimate by +215.04%, and the EPS surprise was +312.68% [12][13] Valuation - Novavax is graded B in the Zacks Value Style Score, indicating it is trading at a discount to its peers, which suggests potential undervaluation [17]

Core Insights - Novavax announced positive results from a late-stage study of its COVID-19-influenza combination (CIC) and standalone influenza vaccine candidates, showing robust immune responses in adults aged 65 and older [1][2][8] - The study's findings will guide the design of another late-stage trial that could support regulatory submissions if successful [3][8] - Novavax is seeking strategic collaborations to finance further development and commercialization of both vaccine candidates as part of a strategic shift to expand its pipeline [4][8] Stock Performance - Novavax shares have underperformed the industry year to date [5] Recent Developments - The announcement followed the FDA's approval of Nuvaxovid for older adults, with a narrower label than expected, restricting use in individuals aged 12-64 with high-risk conditions [7][8] - Sanofi has acquired exclusive global marketing rights for Nuvaxovid, part of a multi-billion-dollar deal, and will receive tiered royalties on future sales [10] Competitive Landscape - Other companies like Pfizer and Moderna are also developing COVID-flu combination vaccines, with Moderna ahead in its investigational candidate mRNA-1083, despite a recent setback [11][12] - Pfizer faced challenges in its phase III study for its combination vaccine, missing one of its primary immunogenicity objectives [13] - Sanofi is testing multiple COVID-19/flu combination vaccine candidates, with two receiving fast-track designation from the FDA [14]

Company Overview - Novavax has transitioned from a vertically integrated commercial organization focused on the launch of its COVID-19 vaccine, Nuvaxovid, to a model that emphasizes research and development (R&D) and diversified partnerships [3][4]. Business Model Evolution - From 2020 to 2022, the majority of Novavax's resources were dedicated to the development and introduction of Nuvaxovid, marking a singular focus on this product [4]. - In early 2023, the company began to evolve its business model to prioritize R&D and establish a broader range of partnerships [3]. Leadership and Presentation - The presentation at the Goldman Sachs 46th Annual Global Healthcare Conference featured key executives, including the CEO, CFO, and the head of R&D, indicating a strong leadership presence [1]. - The conference serves as a platform for Novavax to communicate its strategic direction and business evolution to potential investors and stakeholders [1].

Novavax (NVAX) FY Conference June 11, 2025 02:00 PM ET Speaker0 Are we ready to go? Are we live? Oh, hello, everyone. Speaker1 Hi, I'm John Jacobs, CEO of Novavax, and I'm joined here today by Jim Kelly, our CFO, and Doctor. Roxandra Draghia, who heads up our R and D. I want to thank everyone who's here today to join us and listening in to our presentation at the Goldman Sachs forty sixth Annual Global Healthcare Conference. Today's 06/11/2025. I'll advance the slide to our cautionary note regarding forward ...

Core Insights - The Zacks Premium service provides tools for investors to enhance their stock market strategies and confidence [1] - Zacks Style Scores are designed to help investors select stocks with the highest potential to outperform the market in the short term [2] Zacks Style Scores Overview - The Style Scores consist of four categories: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] - Value Score identifies undervalued stocks using financial ratios [3] - Growth Score assesses a company's financial health and future growth potential [4] - Momentum Score capitalizes on price trends and earnings outlook changes [5] - VGM Score combines all three styles to provide a comprehensive evaluation of stocks [6] Zacks Rank and Performance - The Zacks Rank is a proprietary model that utilizes earnings estimate revisions to guide investment decisions [7] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +25.41%, significantly outperforming the S&P 500 [8] - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal returns [10] Stock Highlight: Novavax (NVAX) - Novavax, Inc. is a biotechnology company focused on developing vaccines for infectious diseases and has a Zacks Rank of 3 (Hold) with a VGM Score of B [12] - The company has a Momentum Style Score of B, with shares increasing by 16.3% in the past four weeks [13] - Recent upward revisions in earnings estimates indicate a positive outlook, with the Zacks Consensus Estimate rising from $1.05 to $2.03 per share [13] - Novavax has an impressive average earnings surprise of 77.9%, making it a noteworthy consideration for investors [13]

Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 Cautionary Note Regarding Forward-Looking Statements This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," and other words of similar meaning. These forward-looking statements address various matters including Novavax's corporate strategy and ...

Core Viewpoint - Novavax, Inc. announced positive results from the initial cohort of its COVID-19-Influenza Combination (CIC) and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza (tNIV) Phase 3 trial, indicating that both vaccine candidates induced immune responses comparable to licensed vaccines Nuvaxovid® and Fluzone HD [1][2][3] Group 1: Trial Results - The Phase 3 trial involved approximately 2,000 adults aged 65 and older, focusing on the safety and immunogenicity of the CIC and tNIV compared to Nuvaxovid and Fluzone HD [3] - Both vaccine candidates demonstrated robust immune responses, with neutralizing antibody responses increasing by 2.4 to 5.7 times over baseline [2][6] - The trial results showed that nearly all solicited adverse events (>98%) were mild or moderate, indicating good tolerability [2][6] Group 2: Future Development - The data from this trial will inform future discussions with potential partners regarding the registrational Phase 3 program for the CIC and tNIV vaccines [2][3] - Novavax continues to seek partnerships to advance the development of these vaccine programs [6]